VelosBio Inc.

Ipsen SA has resumed its oncology shopping spree and moved into the antibody-drug conjugate (ADC) space for the first time by linking up with Sutro Biopharma, Inc. of the US. The French mid-sized p

The pace of decline in biopharma venture capital investment over the past year has been striking: after an impressive first quarter in 2022, when biopharma companies raised $11.9bn, the amount of VC f

Many pharma market analysts had predicted 2022 was going to be a bumper year for mergers and acquisitions, but ten months in, that buying bonanza has yet to materialize. A new analysis from SVB Securi

Merck & Co is in advanced discussions with Seagen about a possible takeover bid, according to the Wall Street Journal , but sources close to talks have said a deal is not yet imminent. The newspap